Sevoflurane (1,1,1,3,3,3-hexafluoro-2-(fluoromethoxy)propane; synonym, fluoromethyl hexafluoroisopropyl ether), is a sweet-smelling, nonflammable, highly fluorinate methyl isopropyl ether use as an inhalational anaesthetic for induction and maintenance of general anesthesia. After desflurane, it is the volatile anesthetic with the fastest onset and offset. Buy Sevoflurane Inhalation Anesthetic
It is one of the most commonly use volatile anesthetic agents, particularly for outpatient anesthesia, across all ages, as well as in veterinary medicine. Together with desflurane, sevoflurane is replacing isoflurane and halothane in modern anesthesiology. It is often administer in a mixture of nitrous oxide and oxygen.
Sevoflurane “has an excellent safety record”, but is under review for potential neurotoxicity, especially relevant to administration in infants and children, and rare reports similar to halothane hepatotoxicity. Sevoflurane is the preferred agent for mask induction due to its lesser irritation to mucous membranes. Buy Sevoflurane Inhalation Anesthetic
Sevoflurane was discover by Ross Terrel and independently by Bernard M Regan. A details report of its development and properties appear in 1975 in a paper author by Richard Wallin, Bernard Regan, Martha Napoli and Ivan Stern. It was introduce into clinical practice initially in Japan in 1990 by Maruishi Pharmaceutical Co., Ltd. Osaka, Japan. The rights for sevoflurane worldwide were held by AbbVie. It is now available as a generic drug.